Clinical Determination of Serum Nardilysin Levels in Predicting 30-Day Mortality among Adults with Malignant Cerebral Infarction.

Fang-Hui Chen,Yi Wang,Yi-Xiang Jiang,Gui-Hong Zhang,Zhi-Min Wang,Hui Yang
DOI: https://doi.org/10.1016/j.cca.2019.03.1608
IF: 6.314
2019-01-01
Clinica Chimica Acta
Abstract:Background: Nardilysin, a kind of metalloendopeptidase, plays an important role in numerous inflammatory diseases. Malignant cerebral infarction (Glasgow coma scale score of < 9) is associated with a high mortality risk. Here, we intended to investigate the relationship between serum nardilysin levels and prognosis of patients with malignant cerebral infarction. Methods: Serum nardilysin concentrations were quantified at malignant cerebral infarction diagnosis moment in 105 patients and at study entrance in 105 healthy controls. Association of nardilysin concentrations with 30-day mortality and overall survival was estimated using multivariate analyses. Results: The patients exhibited substantially increased serum nardilysin concentrations, as compared to the controls. Nardilysin concentrations were in pronounced correlation with Glasgow coma scale scores and serum C-reactive protein concentrations. Serum nardilysin was independently predictive of 30-day mortality and overall survival. Under receiver operating characteristic curve, its high discriminatory ability was found. Conclusions: Rising serum nardilysin concentrations following malignant cerebral infarction are strongly related to stroke severity, inflammatory extent and a higher risk of mortality, substantializing serum nardilysin as a potential prognostic biomarker for malignant cerebral infarction.
What problem does this paper attempt to address?